Drug intelligence / Profile preview

betamethasone + methylprednisolone aceponate

Development stage: Unknown
Lead developer: LEO Pharma
Modality: Small Molecules
Administration: Topical, Intramuscular

Overview

This is a combination of two corticosteroid medications: betamethasone and methylprednisolone aceponate. Both are used to treat inflammatory skin conditions such as eczema and psoriasis. Methylprednisolone aceponate (MPA) is a fourth-generation, non-halogenated topical corticosteroid available as 0.1% ointment/cream formulations. Betamethasone is available in various forms including injectable suspension and topical preparations. Both medications work by suppressing the immune system to reduce inflammation, redness, itching, and allergic reactions.

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on betamethasone + methylprednisolone aceponate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on betamethasone + methylprednisolone aceponate.

Explore the full profile